Oncology & Cancer

A blood test could predict who benefits from immunotherapy

A test which detects changing levels of tumor fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from immunotherapy, a treatment option for advanced cancers.

Medications

Relugolix superior to leuprolide in advanced prostate cancer

(HealthDay)—For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, while enzalutamide is ...

page 1 from 30